Variability in the disposition of intraventricular methotrexate: a proposal for rational dosing.
- 1 November 1989
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 7 (11), 1741-1747
- https://doi.org/10.1200/jco.1989.7.11.1741
Abstract
Despite the clinical experience with Ommaya reservoir-facilitated intraventricular methotrexate (MTX) therapy, established age-related dosage guidelines do not exist. In an attempt to design such a schedule, 49 courses of intra-Ommaya MTX (median dose, 6 mg) administered to 12 patients were studied. Using a fluorescence polarized immunoassay (TDx; Abbott, Dallas, TX), the median peak intraventricular CSF MTX concentration (CSF [MTX]) was 423 mumol/L. Median CSF [MTX] at 24 hours was 4.6 mumol/L, and at 48 hours was 1.05 mumol/L. Median MTX half-life (t1/2) was 5.7 hours. A CSF [MTX] greater than 1 mumol/L was maintained for 24 hours in all but one course and for 48 hours in half of the courses. No correlations were found between MTX dose, patient age, [MTX], t1/2 or prior therapy. Considerable intra- and interpatient variability was seen in MTX disposition, emphasizing the need to monitor [MTX] with each course. A schedule for intraventricular MTX with an initial dose of 6 mg and supplemental doses of 6, 4, or 2 mg at 24 and 48 hours according to serial measurements of intraventricular [MTX] should be initiated to provide a minimum CSF [MTX] of 1 mumol/L for 72 hours.This publication has 6 references indexed in Scilit:
- Altered central nervous system pharmacology of methotrexate in childhood leukemia: another sign of meningeal relapse.Journal of Clinical Oncology, 1985
- Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitisAmerican Journal Of Medicine, 1982
- Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphomaCancer, 1982
- METHOTREXATE CYTO-TOXICITY FOR L5178Y/ASN-LYMPHOBLASTS - RELATIONSHIP OF DOSE AND DURATION OF EXPOSURE TO TUMOR-CELL VIABILITY1982
- Proliferative kinetics of the leukemic cells in meningeal leukemiaCancer, 1978
- CONCENTRATION X TIME METHOTREXATE VIA A SUBCUTANEOUS RESERVOIR - LESS TOXIC REGIMEN FOR INTRA-VENTRICULAR CHEMOTHERAPY OF CENTRAL NERVOUS-SYSTEM NEOPLASMS1978